Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

(1) Background: Secondary acute myeloid leukemia (AML), i.e., AML arising from prior therapy (therapy-related) and/or an antecedent hematologic disorder (AHD) is generally associated with worse outcomes compared to de novo AML. However, recognizing the prognostic importance of genetic characteristic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2023-01, Vol.15 (2), p.352
Hauptverfasser: Orvain, Corentin, Rodríguez-Arbolí, Eduardo, Othus, Megan, Sandmaier, Brenda M, Deeg, H Joachim, Appelbaum, Frederick R, Walter, Roland B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 352
container_title Cancers
container_volume 15
creator Orvain, Corentin
Rodríguez-Arbolí, Eduardo
Othus, Megan
Sandmaier, Brenda M
Deeg, H Joachim
Appelbaum, Frederick R
Walter, Roland B
description (1) Background: Secondary acute myeloid leukemia (AML), i.e., AML arising from prior therapy (therapy-related) and/or an antecedent hematologic disorder (AHD) is generally associated with worse outcomes compared to de novo AML. However, recognizing the prognostic importance of genetic characteristics rather than clinical history, secondary AML is now considered a diagnostic qualifier rather than a separate disease entity. (2) Methods: To assess the association between clinical history and AML outcomes in the context of allogeneic hematopoietic cell transplantation (HCT), we retrospectively analyzed 759 patients with de novo AML, 115 with AHD AML, and 105 with therapy-related AML who received first allografts while in first or second remission. (3) Results: At the time of HCT, these three cohorts differed significantly regarding many patient and disease-specific characteristics, including age (p < 0.001), gender (p < 0.001), disease risk (p = 0.005), HCT-CI score (p < 0.001), blood count recovery (p = 0.003), first vs. second remission (p < 0.001), remission duration (p < 0.001), measurable residual disease (MRD; p < 0.001), and conditioning intensity (p < 0.001). Relative to patients with de novo AML, relapse rates were similar for patients with AHD (hazard ratio [HR] = 1.07, p = 0.7) and therapy-related AML (HR = 0.86, p = 0.4) after multivariable adjustment, as were relapse-free survival (HR = 1.20, p = 0.2, and HR = 0.89, p = 0.5) and overall survival (HR = 1.19, p = 0.2, and HR = 0.93, p = 0.6). Non-relapse mortality was higher for AHD AML (HR = 1.59, p = 0.047). (4) Conclusions: These data suggest that the clinical history by itself contains limited prognostic value for adults with AML undergoing allografting, supporting the most recent approach to use this information as a diagnostic qualifier rather than a disease entity.
doi_str_mv 10.3390/cancers15020352
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9856876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2768229987</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-25a885202952204278b53496a6da7c8fb2a7f04ad4bde87a6ba2253cb4c1b5563</originalsourceid><addsrcrecordid>eNpdkk1v1DAQhiMEolXpmRuyxIVDlzp2_JELUrQUirSoHJZzNHEmrUtiB9sB9kf1P-LVlqp0Lp7RPPNqXnmK4nVJ33Ne03MDzmCIpaCMcsGeFceMKraSsq6eP8qPitMYb2kOzksl1cviiEupGKf8uLhrYvTGQrLekQ7Tb0RHvgXrA1nvkk_-jzVke4MB5t0ZaVxCgz26RC5xguRHf537H230ocdwRsD15GpJxk9IYEgYSDNmBh1m7DAye4spV2scR7IN4OI8gkuHDawjTb-MiTRmSUi-7nD0ticbXH7gZOFV8WKAMeLp_XtSfP90sV1frjZXn7-sm83KVKxMKyZAa8EoqwVjtGJKd4JXtQTZgzJ66BiogVbQV12PWoHsgDHBTVeZshNC8pPiw0F3XroJe5MNBxjbOdgJwq71YNv_O87etNf-V1trIbXaC7y7Fwj-54IxtZONJjsGh36JLVNSM1bXWmX07RP01i_BZXt7SpVaV7TK1PmBMsHHGHB4WKak7f4a2ifXkCfePPbwwP_7e_4XXmK1Zw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2767188404</pqid></control><display><type>article</type><title>Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Orvain, Corentin ; Rodríguez-Arbolí, Eduardo ; Othus, Megan ; Sandmaier, Brenda M ; Deeg, H Joachim ; Appelbaum, Frederick R ; Walter, Roland B</creator><creatorcontrib>Orvain, Corentin ; Rodríguez-Arbolí, Eduardo ; Othus, Megan ; Sandmaier, Brenda M ; Deeg, H Joachim ; Appelbaum, Frederick R ; Walter, Roland B</creatorcontrib><description><![CDATA[(1) Background: Secondary acute myeloid leukemia (AML), i.e., AML arising from prior therapy (therapy-related) and/or an antecedent hematologic disorder (AHD) is generally associated with worse outcomes compared to de novo AML. However, recognizing the prognostic importance of genetic characteristics rather than clinical history, secondary AML is now considered a diagnostic qualifier rather than a separate disease entity. (2) Methods: To assess the association between clinical history and AML outcomes in the context of allogeneic hematopoietic cell transplantation (HCT), we retrospectively analyzed 759 patients with de novo AML, 115 with AHD AML, and 105 with therapy-related AML who received first allografts while in first or second remission. (3) Results: At the time of HCT, these three cohorts differed significantly regarding many patient and disease-specific characteristics, including age (p < 0.001), gender (p < 0.001), disease risk (p = 0.005), HCT-CI score (p < 0.001), blood count recovery (p = 0.003), first vs. second remission (p < 0.001), remission duration (p < 0.001), measurable residual disease (MRD; p < 0.001), and conditioning intensity (p < 0.001). Relative to patients with de novo AML, relapse rates were similar for patients with AHD (hazard ratio [HR] = 1.07, p = 0.7) and therapy-related AML (HR = 0.86, p = 0.4) after multivariable adjustment, as were relapse-free survival (HR = 1.20, p = 0.2, and HR = 0.89, p = 0.5) and overall survival (HR = 1.19, p = 0.2, and HR = 0.93, p = 0.6). Non-relapse mortality was higher for AHD AML (HR = 1.59, p = 0.047). (4) Conclusions: These data suggest that the clinical history by itself contains limited prognostic value for adults with AML undergoing allografting, supporting the most recent approach to use this information as a diagnostic qualifier rather than a disease entity.]]></description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15020352</identifier><identifier>PMID: 36672303</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acute myeloid leukemia ; Allografts ; Blood tests ; Bone marrow ; Breast cancer ; Cancer therapies ; Chemotherapy ; Classification ; Cytotoxicity ; Hematological diseases ; Leukemia ; Medical prognosis ; Mortality ; Patients ; Remission ; Remission (Medicine) ; Transplantation</subject><ispartof>Cancers, 2023-01, Vol.15 (2), p.352</ispartof><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-25a885202952204278b53496a6da7c8fb2a7f04ad4bde87a6ba2253cb4c1b5563</citedby><cites>FETCH-LOGICAL-c421t-25a885202952204278b53496a6da7c8fb2a7f04ad4bde87a6ba2253cb4c1b5563</cites><orcidid>0000-0002-9268-3341</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856876/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856876/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36672303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orvain, Corentin</creatorcontrib><creatorcontrib>Rodríguez-Arbolí, Eduardo</creatorcontrib><creatorcontrib>Othus, Megan</creatorcontrib><creatorcontrib>Sandmaier, Brenda M</creatorcontrib><creatorcontrib>Deeg, H Joachim</creatorcontrib><creatorcontrib>Appelbaum, Frederick R</creatorcontrib><creatorcontrib>Walter, Roland B</creatorcontrib><title>Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description><![CDATA[(1) Background: Secondary acute myeloid leukemia (AML), i.e., AML arising from prior therapy (therapy-related) and/or an antecedent hematologic disorder (AHD) is generally associated with worse outcomes compared to de novo AML. However, recognizing the prognostic importance of genetic characteristics rather than clinical history, secondary AML is now considered a diagnostic qualifier rather than a separate disease entity. (2) Methods: To assess the association between clinical history and AML outcomes in the context of allogeneic hematopoietic cell transplantation (HCT), we retrospectively analyzed 759 patients with de novo AML, 115 with AHD AML, and 105 with therapy-related AML who received first allografts while in first or second remission. (3) Results: At the time of HCT, these three cohorts differed significantly regarding many patient and disease-specific characteristics, including age (p < 0.001), gender (p < 0.001), disease risk (p = 0.005), HCT-CI score (p < 0.001), blood count recovery (p = 0.003), first vs. second remission (p < 0.001), remission duration (p < 0.001), measurable residual disease (MRD; p < 0.001), and conditioning intensity (p < 0.001). Relative to patients with de novo AML, relapse rates were similar for patients with AHD (hazard ratio [HR] = 1.07, p = 0.7) and therapy-related AML (HR = 0.86, p = 0.4) after multivariable adjustment, as were relapse-free survival (HR = 1.20, p = 0.2, and HR = 0.89, p = 0.5) and overall survival (HR = 1.19, p = 0.2, and HR = 0.93, p = 0.6). Non-relapse mortality was higher for AHD AML (HR = 1.59, p = 0.047). (4) Conclusions: These data suggest that the clinical history by itself contains limited prognostic value for adults with AML undergoing allografting, supporting the most recent approach to use this information as a diagnostic qualifier rather than a disease entity.]]></description><subject>Acute myeloid leukemia</subject><subject>Allografts</subject><subject>Blood tests</subject><subject>Bone marrow</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Classification</subject><subject>Cytotoxicity</subject><subject>Hematological diseases</subject><subject>Leukemia</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Patients</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Transplantation</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkk1v1DAQhiMEolXpmRuyxIVDlzp2_JELUrQUirSoHJZzNHEmrUtiB9sB9kf1P-LVlqp0Lp7RPPNqXnmK4nVJ33Ne03MDzmCIpaCMcsGeFceMKraSsq6eP8qPitMYb2kOzksl1cviiEupGKf8uLhrYvTGQrLekQ7Tb0RHvgXrA1nvkk_-jzVke4MB5t0ZaVxCgz26RC5xguRHf537H230ocdwRsD15GpJxk9IYEgYSDNmBh1m7DAye4spV2scR7IN4OI8gkuHDawjTb-MiTRmSUi-7nD0ticbXH7gZOFV8WKAMeLp_XtSfP90sV1frjZXn7-sm83KVKxMKyZAa8EoqwVjtGJKd4JXtQTZgzJ66BiogVbQV12PWoHsgDHBTVeZshNC8pPiw0F3XroJe5MNBxjbOdgJwq71YNv_O87etNf-V1trIbXaC7y7Fwj-54IxtZONJjsGh36JLVNSM1bXWmX07RP01i_BZXt7SpVaV7TK1PmBMsHHGHB4WKak7f4a2ifXkCfePPbwwP_7e_4XXmK1Zw</recordid><startdate>20230105</startdate><enddate>20230105</enddate><creator>Orvain, Corentin</creator><creator>Rodríguez-Arbolí, Eduardo</creator><creator>Othus, Megan</creator><creator>Sandmaier, Brenda M</creator><creator>Deeg, H Joachim</creator><creator>Appelbaum, Frederick R</creator><creator>Walter, Roland B</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9268-3341</orcidid></search><sort><creationdate>20230105</creationdate><title>Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia</title><author>Orvain, Corentin ; Rodríguez-Arbolí, Eduardo ; Othus, Megan ; Sandmaier, Brenda M ; Deeg, H Joachim ; Appelbaum, Frederick R ; Walter, Roland B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-25a885202952204278b53496a6da7c8fb2a7f04ad4bde87a6ba2253cb4c1b5563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute myeloid leukemia</topic><topic>Allografts</topic><topic>Blood tests</topic><topic>Bone marrow</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Classification</topic><topic>Cytotoxicity</topic><topic>Hematological diseases</topic><topic>Leukemia</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Patients</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orvain, Corentin</creatorcontrib><creatorcontrib>Rodríguez-Arbolí, Eduardo</creatorcontrib><creatorcontrib>Othus, Megan</creatorcontrib><creatorcontrib>Sandmaier, Brenda M</creatorcontrib><creatorcontrib>Deeg, H Joachim</creatorcontrib><creatorcontrib>Appelbaum, Frederick R</creatorcontrib><creatorcontrib>Walter, Roland B</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orvain, Corentin</au><au>Rodríguez-Arbolí, Eduardo</au><au>Othus, Megan</au><au>Sandmaier, Brenda M</au><au>Deeg, H Joachim</au><au>Appelbaum, Frederick R</au><au>Walter, Roland B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-01-05</date><risdate>2023</risdate><volume>15</volume><issue>2</issue><spage>352</spage><pages>352-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract><![CDATA[(1) Background: Secondary acute myeloid leukemia (AML), i.e., AML arising from prior therapy (therapy-related) and/or an antecedent hematologic disorder (AHD) is generally associated with worse outcomes compared to de novo AML. However, recognizing the prognostic importance of genetic characteristics rather than clinical history, secondary AML is now considered a diagnostic qualifier rather than a separate disease entity. (2) Methods: To assess the association between clinical history and AML outcomes in the context of allogeneic hematopoietic cell transplantation (HCT), we retrospectively analyzed 759 patients with de novo AML, 115 with AHD AML, and 105 with therapy-related AML who received first allografts while in first or second remission. (3) Results: At the time of HCT, these three cohorts differed significantly regarding many patient and disease-specific characteristics, including age (p < 0.001), gender (p < 0.001), disease risk (p = 0.005), HCT-CI score (p < 0.001), blood count recovery (p = 0.003), first vs. second remission (p < 0.001), remission duration (p < 0.001), measurable residual disease (MRD; p < 0.001), and conditioning intensity (p < 0.001). Relative to patients with de novo AML, relapse rates were similar for patients with AHD (hazard ratio [HR] = 1.07, p = 0.7) and therapy-related AML (HR = 0.86, p = 0.4) after multivariable adjustment, as were relapse-free survival (HR = 1.20, p = 0.2, and HR = 0.89, p = 0.5) and overall survival (HR = 1.19, p = 0.2, and HR = 0.93, p = 0.6). Non-relapse mortality was higher for AHD AML (HR = 1.59, p = 0.047). (4) Conclusions: These data suggest that the clinical history by itself contains limited prognostic value for adults with AML undergoing allografting, supporting the most recent approach to use this information as a diagnostic qualifier rather than a disease entity.]]></abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36672303</pmid><doi>10.3390/cancers15020352</doi><orcidid>https://orcid.org/0000-0002-9268-3341</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2023-01, Vol.15 (2), p.352
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9856876
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central
subjects Acute myeloid leukemia
Allografts
Blood tests
Bone marrow
Breast cancer
Cancer therapies
Chemotherapy
Classification
Cytotoxicity
Hematological diseases
Leukemia
Medical prognosis
Mortality
Patients
Remission
Remission (Medicine)
Transplantation
title Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T04%3A42%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20Prior%20Cytotoxic%20Therapy,%20Antecedent%20Hematologic%20Disorder,%20and%20Outcome%20after%20Allogeneic%20Hematopoietic%20Cell%20Transplantation%20in%20Adult%20Acute%20Myeloid%20Leukemia&rft.jtitle=Cancers&rft.au=Orvain,%20Corentin&rft.date=2023-01-05&rft.volume=15&rft.issue=2&rft.spage=352&rft.pages=352-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15020352&rft_dat=%3Cproquest_pubme%3E2768229987%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2767188404&rft_id=info:pmid/36672303&rfr_iscdi=true